Rebastinib (DCC-2036) is an orally active, non-ATP-competitive Bcr-Abl inhibitor for Abl1WT and Abl1T315I with IC50s of 0.8 nM and 4 nM, respectively. Rebastinib also inhibits SRC, KDR, FLT3, and Tie-2, and has low activity to seen towards c-Kit.
Molecular Weight:
553.59
Purity:
99.91
CAS Number:
[1020172-07-9]
Formula:
C30H28FN7O3
Target:
Apoptosis,Bcr-Abl,FLT3,Src
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
